DiaMedica End Period Cash Flow from 2010 to 2024
| DMAC Stock | USD 5.16 0.17 3.19% |
End Period Cash Flow | First Reported 2006-12-31 | Previous Quarter 14.1 M | Current Value 4.1 M | Quarterly Volatility 3.2 M |
Check DiaMedica Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DiaMedica Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 K, Interest Expense of 426.2 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 49.24, Dividend Yield of 0.0 or PTB Ratio of 1.72. DiaMedica financial statements analysis is a perfect complement when working with DiaMedica Therapeutics Valuation or Volatility modules.
DiaMedica | End Period Cash Flow |
Latest DiaMedica Therapeutics' End Period Cash Flow Growth Pattern
Below is the plot of the End Period Cash Flow of DiaMedica Therapeutics over the last few years. It is DiaMedica Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DiaMedica Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
DiaMedica End Period Cash Flow Regression Statistics
| Arithmetic Mean | 3,769,352 | |
| Geometric Mean | 1,635,888 | |
| Coefficient Of Variation | 110.03 | |
| Mean Deviation | 2,596,918 | |
| Median | 2,651,971 | |
| Standard Deviation | 4,147,438 | |
| Sample Variance | 17.2T | |
| Range | 16.8M | |
| R-Value | 0.39 | |
| Mean Square Error | 15.8T | |
| R-Squared | 0.15 | |
| Significance | 0.15 | |
| Slope | 358,533 | |
| Total Sum of Squares | 240.8T |
DiaMedica End Period Cash Flow History
About DiaMedica Therapeutics Financial Statements
DiaMedica Therapeutics stakeholders use historical fundamental indicators, such as DiaMedica Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although DiaMedica Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DiaMedica Therapeutics' assets and liabilities are reflected in the revenues and expenses on DiaMedica Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DiaMedica Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| End Period Cash Flow | 4.5 M | 3.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out the analysis of DiaMedica Therapeutics Correlation against competitors. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.